Minerva Neurosciences, a clinical-stage biotech developing treatments for central nervous system diseases, raised $33 million by offering 5.5 million shares at $6.00, as expected. Minerva Neurosciences plans to list on the NASDAQ under the symbol NERV. Minerva Neurosciences initially filed confidentially on 2/14/2014. Jefferies & Co. acted as the sole bookrunner on the deal.
